

# Benjamin A Teply

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5920828/benjamin-a-teply-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

42  
papers

4,001  
citations

15  
h-index

44  
g-index

44  
ext. papers

4,453  
ext. citations

6.3  
avg, IF

4.76  
L-index

#	Paper	IF	Citations
42	Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 6315-20	11.5	1448
41	Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. <i>Biomaterials</i> , <b>2007</b> , 28, 869-76	15.6	1053
40	Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 2586-91	11.5	596
39	Microfluidic system for studying the interaction of nanoparticles and microparticles with cells. <i>Analytical Chemistry</i> , <b>2005</b> , 77, 5453-9	7.8	145
38	Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection. <i>ACS Nano</i> , <b>2012</b> , 6, 696-704	16.7	136
37	Magnetically responsive polymeric microparticles for oral delivery of protein drugs. <i>Pharmaceutical Research</i> , <b>2006</b> , 23, 557-64	4.5	113
36	Collagen composite hydrogels for vocal fold lamina propria restoration. <i>Biomaterials</i> , <b>2006</b> , 27, 1104-9	15.6	108
35	Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. <i>Lancet Oncology</i> , <b>2018</b> , 19, 76-86	21.7	100
34	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2021</b> , 19, 134-143	7.3	71
33	The use of charge-coupled polymeric microparticles and micromagnets for modulating the bioavailability of orally delivered macromolecules. <i>Biomaterials</i> , <b>2008</b> , 29, 1216-23	15.6	53
32	Treatment strategies for DNA repair-deficient prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , <b>2017</b> , 10, 889-898	3.8	21
31	Extreme Response to High-dose Testosterone in BRCA2- and ATM-mutated Prostate Cancer. <i>European Urology</i> , <b>2017</b> , 71, 499	10.2	19
30	A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. <i>European Urology</i> , <b>2021</b> , 79, 692-699	10.2	17
29	Chemotherapy options in castration-resistant prostate cancer. <i>Indian Journal of Urology</i> , <b>2016</b> , 32, 262-270	7.8	16
28	Sildenafil Potentiates the Therapeutic Efficacy of Docetaxel in Advanced Prostate Cancer by Stimulating NO-cGMP Signaling. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5720-5734	12.9	15
27	Novel treatment strategy for refractory hemorrhagic cystitis following radiation treatment of genitourinary cancer: Use of 980-nm diode laser. <i>Lasers in Medical Science</i> , <b>2012</b> , 27, 1099-102	3.1	13
26	Systemic therapy for bladder cancer - a medical oncologist's perspective. <i>Journal of Solid Tumors</i> , <b>2014</b> , 4, 25-35	0.3	12

25	Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , <b>2016</b> , 23, 279-90	4	10
24	Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2486-2496	2.2	10
23	Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2020</b> , 1874, 188383	11.2	9
22	Impact of performance status on response and survival among patients receiving checkpoint inhibitors for advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 12028-12028	2.2	5
21	Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1536-1543	13.4	5
20	Targeting resistant prostate cancer with ATR and PARP inhibition (TRAP trial): A phase II study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS254-TPS254	2.2	4
19	Targeting treatment options for castration-resistant prostate cancer. <i>American Journal of Clinical and Experimental Urology</i> , <b>2021</b> , 9, 101-120	1.6	4
18	Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients. <i>Annals of Pharmacotherapy</i> , <b>2021</b> , 10600280211033938	2.9	4
17	Nanoparticle-aptamer bioconjugates for targeted antineoplastic drug delivery. <i>American Journal of Drug Delivery</i> , <b>2006</b> , 4, 123-130		3
16	Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors. <i>JCO Oncology Practice</i> , <b>2021</b> , OP2001055	2.3	3
15	Aptamer Conjugates: Emerging Delivery Platforms for Targeted Cancer Therapy <b>2011</b> , 1263-1281		2
14	Tumor- and osteoclast-derived NRP2 in prostate cancer bone metastases. <i>Bone Research</i> , <b>2021</b> , 9, 24	13.3	2
13	Patterns of metastatic disease progression after treatment with first-line enzalutamide or abiraterone in castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e16539-e16539	2.2	1
12	Phase II study of olaparib (without ADT) in men with high-risk biochemically-recurrent prostate cancer following prostatectomy, with integrated biomarker analysis.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS386-TPS386	2.2	1
11	Biomarkers for Treatment Response in Advanced Prostate Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
10	A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4507-4507	2.2	1
9	Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302. <i>Prostate</i> , <b>2019</b> , 79, 929-933	4.2	0
8	RESTORE: A single-arm, open-label phase II trial of bipolar androgen therapy (BAT) in men with metastatic castration resistant prostate cancer (mCRPC)A comparison of post-abiraterone (Abi) versus post-enzalutamide (Enza) patients (Pts).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5576-5576	2.2	0

- 7 Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities. *Medicine (United States)*, **2021**, 100, e28199 1.8 ○
- 6 Magnetite-PLGA Microparticles for Oral Delivery of Insulin. *Materials Research Society Symposia Proceedings*, **2005**, 873, 1
- 5 Visceral metastases on abiraterone vs. placebo: A post-hoc analysis of mode of radiographic progression in COU-AA-302.. *Journal of Clinical Oncology*, **2018**, 36, 194-194 2.2
- 4 Anticipating the Next Challenging Clinical Dilemmas in Prostate Cancer. *JCO Oncology Practice*, **2020**, 16, 791-792 2.3
- 3 Can patients with advanced malignancy and poor performance status benefit from nivolumab plus ipilimumab as a palliative treatment?. *Journal of Clinical Oncology*, **2021**, 39, 12028-12028 2.2
- 2 Current Management of Refractory Germ Cell Tumors. *Current Oncology Reports*, **2021**, 23, 101 6.3
- 1 Navigating an Optimal Treatment Course for Advanced Kidney Cancer. *Oncology*, **2021**, 35, 308-309 1.8